Developer docs
API playgroundTry for free, no card

Search company profiles

Latus Bio

Full company profile

uuid0000f6r

Namestring
Latus Bio
Legal namestring
Latus Bio, Inc.
Websiteurl
latusbio.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Latus Bio is a clinical-stage biotechnology company developing AAV-based gene therapies for central nervous system (CNS) and peripheral diseases, founded in 2024 and headquartered in Philadelphia with operations in Boston. The company's core offering is a proprietary AAV discovery and engineering platform that combines unbiased non-human primate screening with AI/ML-driven design, built on a dataset of over 100 million unique route-capsid-tissue-cell type combinations from nine in vivo NHP campaigns. Two lead engineered capsid variants — AAV-DB-3 (for deep brain delivery to the striatum) and AAV-Ep+ (for broad CNS distribution via CSF protein secretion) — power the lead programs and have demonstrated 100x+ greater potency than traditional AAV5 vectors in preclinical primate studies, with claimed dose requirements 1/100 to 1/10,000 of competitors and cost of goods less than 1/10 of competing approaches.

The company's clinical pipeline is concentrated in two ultra-rare CNS programs: LTS-201, an AAV-DB-3-based gene therapy targeting the MSH3 gene for Huntington's disease (IND submission planned Q3 2026), and LTS-101, an AAV-Ep+-based gene therapy delivering functional TPP1 for CLN2 (Batten) disease (FDA IND cleared in December 2025 with Orphan Drug, Rare Pediatric Disease, and Fast Track designations). The platform is licensed from Children's Hospital of Philadelphia, and the company plans to expand into broader CNS indications (Parkinson's, lysosomal storage disorders) and peripheral tissues (liver, muscle, kidney, heart, eye, ear), as well as pursue strategic partnerships to license capsid technology to other gene therapy developers.

As a pre-revenue clinical-stage biotech, Latus Bio is funded entirely by equity capital, having raised $97 million in total Series A financing ($54M initial close in May 2024 led by 8VC and DCVC Bio, plus a $43M extension in May 2026). The company plans to commercialize gene therapies through specialty treatment centers and hospital pharmacies upon potential FDA approval, with revenue expected from one-time high-price product sales and potential platform licensing/royalties. Leadership includes CEO P. Peter Ghoroghchian, founder and SAB Chair Beverly Davidson (a leading gene therapy expert from CHOP and 2026 ASGCT Outstanding Achievement Award recipient), CSMO Jang-Ho Cha, CDO John Connelly, CBO Bethany Mancilla, and COO Ainslie Little.

Short descriptiontext

Latus Bio is a clinical-stage biotech developing AAV-based gene therapies for CNS disorders using proprietary engineered capsids (AAV-DB-3, AAV-Ep+) and AI/ML-driven discovery, with lead programs in Huntington's disease and CLN2 Batten disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, CNS therapeutics, AAV capsid engineering, neurodegenerative disease treatment, viral vector delivery
Industry4 codes
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech. Revenue will be generated through commercialization of proprietary gene therapy candidates (LTS-201, LTS-101) upon FDA approval. Gene therapies are typically high-price, one-time or durable treatments with potential for premium reimbursement.

latusbio.com
2Platform Licensing / Strategic Partnerships
TypeLicensing Royalties
Description

Company has indicated plans to pursue strategic partnerships to expand its AAV capsid platform beyond its own pipeline, potentially licensing proprietary capsid technology to other gene therapy developers for additional indications.

biopharmadive.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1LTS-101
Description

Gene therapy candidate for CLN2 disease using AAV-Ep+ capsid to deliver TPP1 throughout the CNS.

latusbio.com
+3 more records
Core offering1 text field

Latus Bio is a clinical-stage biotechnology company developing AAV-based gene therapy candidates for central nervous system (CNS) disorders. Its lead programs are LTS-201 for Huntington's disease and LTS-101 for CLN2 (Batten) disease, both built on proprietary engineered AAV capsid variants (AAV-DB-3 and AAV-Ep+) discovered through unbiased NHP screening and AI/ML-driven design to enable low-dose, targeted gene delivery to deep brain regions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100x or greater potency vs. traditional AAV5 vectors in non-human primate studies for deep brain regions
+4 more records
Product overview1 text field

Latus Bio is a biotechnology company developing AAV gene therapies for central nervous system (CNS) and peripheral diseases. The company's core offering is its AAV discovery and engineering platform, which combines proprietary engineered AAV capsid variants with optimized routes of administration to enable low-dose, cell-specific gene therapy delivery. The platform supports two lead clinical-stage product candidates: LTS-101 (using the AAV-Ep+ capsid) for CLN2 disease, and LTS-201 (using the AAV.DB-3 capsid) for Huntington's disease. The company's approach leverages AI/ML-driven capsid and payload engineering to improve targeting precision, reduce dosage requirements, and address scalability limitations that have traditionally confined gene therapy to ultra-rare diseases.

Product and service3 records
1LTS-101
CategoryGene therapy product candidate
Description

Gene therapy candidate exploiting the AAV-Ep+ capsid to deliver functional TPP1 throughout the CNS for treatment of CLN2 disease, a fatal ultra-rare neurodegenerative lysosomal storage disorder.

2LTS-201
CategoryGene therapy product candidate
Description

Gene therapy candidate using the AAV-DB-3 capsid targeting the MSH3 gene to inhibit somatic CAG repeat expansion in Huntington's disease, intended to delay or halt disease progression.

3AAV Capsid Discovery and Engineering Platform
CategoryTechnology platform (potentially licensable)
Description

Integrated AAV discovery platform combining AI/ML computational methods with unbiased NHP screens to identify novel AAV capsid variants matched to optimized routes of administration; supports potential licensing to other gene therapy developers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Dr. Pranam Chatterjee (University of Pennsylvania)
Strategic tierMinorTypeOthersAnnounced on2025-11-03
Description

Added to Scientific Advisory Board as an expert in peptide and protein modeling to support Latus Bio's AI/ML-driven capsid and payload engineering strategy.

bioadvance.com
2Dr. Philip Kim (University of Toronto)
Strategic tierMinorTypeOthersAnnounced on2025-11-03
Description

Added to Scientific Advisory Board as an expert in peptide and protein modeling to advance Latus Bio's three AI/ML focus areas: AAV capsid engineering, payload engineering, and bespoke therapeutic tailoring.

bioadvance.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-02
Description

Latus Bio was co-founded based on proprietary capsid technology licensed from CHOP. This is the foundational technology relationship underlying the company's entire platform. Beverly Davidson, Ph.D., formerly of CHOP, is the company's founder and SAB Chair.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Engineered AAV capsid development company with structural and computational design capabilities, directly comparable to Latus's capsid engineering platform focus.

TypeDirect peer
Description

Clinical-stage gene therapy company with CNS and cardiac programs leveraging AAV delivery, comparable as a similarly staged competitor in CNS-targeted AAV gene therapy development.

TypeEmerging player
Description

Gene therapy company developing engineered AAV capsids with AI/ML-driven discovery for CNS and other tissues, directly comparable to Latus's capsid engineering platform and AI/ML discovery approach.

TypeDirect peer
Description

Clinical-stage CNS gene therapy company with multiple AAV-based programs for rare neurological diseases, comparable in pipeline focus, stage, and platform approach to Latus.

TypeBroad incumbent
Description

Established AAV gene therapy platform company with multiple clinical and commercial programs, serving as both a potential licensor/licensing partner and a competitor with deeper manufacturing and clinical capabilities.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company focused on CNS diseases including Huntington's and ALS, with proprietary capsid engineering efforts — overlapping directly with Latus's capsid platform and CNS pipeline strategy.

TypeDirect peer
Description

Commercial-stage gene therapy company focused on rare diseases with a non-replicating viral vector platform, providing a comparable business model reference for ultra-rare disease gene therapy commercialization.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AMT-130 for Huntington's disease using AAV delivery to the CNS — a direct competitor to Latus's LTS-201 program with a similar indication and approach.

TypeBroad incumbent
Description

Established gene therapy company (now part of Roche) with commercial gene therapy products, providing a comparable reference for AAV-based therapeutic development and a potential strategic acquirer/licensing partner.

TypeEmerging player
Description

Gene therapy company with engineered AAV capsid platform targeting CNS and other tissues, directly comparable to Latus's approach of capsid engineering for tissue-specific delivery in CNS disorders.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Latus Bio

Gene Therapylatusbio.com

Latus Bio is a clinical-stage biotech developing AAV-based gene therapies for CNS disorders using proprietary engineered capsids (AAV-DB-3, AAV-Ep+) and AI/ML-driven discovery, with lead programs in Huntington's disease and CLN2 Batten disease.

What Latus Bio does

Latus Bio is a clinical-stage biotechnology company developing AAV-based gene therapies for central nervous system (CNS) and peripheral diseases, founded in 2024 and headquartered in Philadelphia with operations in Boston. The company's core offering is a proprietary AAV discovery and engineering platform that combines unbiased non-human primate screening with AI/ML-driven design, built on a dataset of over 100 million unique route-capsid-tissue-cell type combinations from nine in vivo NHP campaigns. Two lead engineered capsid variants — AAV-DB-3 (for deep brain delivery to the striatum) and AAV-Ep+ (for broad CNS distribution via CSF protein secretion) — power the lead programs and have demonstrated 100x+ greater potency than traditional AAV5 vectors in preclinical primate studies, with claimed dose requirements 1/100 to 1/10,000 of competitors and cost of goods less than 1/10 of competing approaches.

The company's clinical pipeline is concentrated in two ultra-rare CNS programs: LTS-201, an AAV-DB-3-based gene therapy targeting the MSH3 gene for Huntington's disease (IND submission planned Q3 2026), and LTS-101, an AAV-Ep+-based gene therapy delivering functional TPP1 for CLN2 (Batten) disease (FDA IND cleared in December 2025 with Orphan Drug, Rare Pediatric Disease, and Fast Track designations). The platform is licensed from Children's Hospital of Philadelphia, and the company plans to expand into broader CNS indications (Parkinson's, lysosomal storage disorders) and peripheral tissues (liver, muscle, kidney, heart, eye, ear), as well as pursue strategic partnerships to license capsid technology to other gene therapy developers.

As a pre-revenue clinical-stage biotech, Latus Bio is funded entirely by equity capital, having raised $97 million in total Series A financing ($54M initial close in May 2024 led by 8VC and DCVC Bio, plus a $43M extension in May 2026). The company plans to commercialize gene therapies through specialty treatment centers and hospital pharmacies upon potential FDA approval, with revenue expected from one-time high-price product sales and potential platform licensing/royalties. Leadership includes CEO P. Peter Ghoroghchian, founder and SAB Chair Beverly Davidson (a leading gene therapy expert from CHOP and 2026 ASGCT Outstanding Achievement Award recipient), CSMO Jang-Ho Cha, CDO John Connelly, CBO Bethany Mancilla, and COO Ainslie Little.

Latus Bio firmographics

Firmographics
Name
Latus Bio
Legal name
Latus Bio, Inc.
Website
https://latusbio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Latus Bio is a clinical-stage biotech developing AAV-based gene therapies for CNS disorders using proprietary engineered capsids (AAV-DB-3, AAV-Ep+) and AI/ML-driven discovery, with lead programs in Huntington's disease and CLN2 Batten disease.
Ownership category
akta.pro rank

Latus Bio industry classification

Industry
Product category
Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV gene therapy
  • CNS therapeutics
  • AAV capsid engineering
  • Neurodegenerative disease treatment
  • Viral vector delivery

Where Latus Bio is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Latus Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Gene Therapy Product Sales: Pre-revenue clinical-stage biotech. Revenue will be generated through commercialization of proprietary gene therapy candidates (LTS-201, LTS-101) upon FDA approval. Gene therapies are typically high-price, one-time or durable treatments with potential for premium reimbursement.
  2. Platform Licensing / Strategic Partnerships: Company has indicated plans to pursue strategic partnerships to expand its AAV capsid platform beyond its own pipeline, potentially licensing proprietary capsid technology to other gene therapy developers for additional indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Latus Bio product offering

Product offering

Core offering

Latus Bio is a clinical-stage biotechnology company developing AAV-based gene therapy candidates for central nervous system (CNS) disorders. Its lead programs are LTS-201 for Huntington's disease and LTS-101 for CLN2 (Batten) disease, both built on proprietary engineered AAV capsid variants (AAV-DB-3 and AAV-Ep+) discovered through unbiased NHP screening and AI/ML-driven design to enable low-dose, targeted gene delivery to deep brain regions.

Product overview

Latus Bio is a biotechnology company developing AAV gene therapies for central nervous system (CNS) and peripheral diseases. The company's core offering is its AAV discovery and engineering platform, which combines proprietary engineered AAV capsid variants with optimized routes of administration to enable low-dose, cell-specific gene therapy delivery. The platform supports two lead clinical-stage product candidates: LTS-101 (using the AAV-Ep+ capsid) for CLN2 disease, and LTS-201 (using the AAV.DB-3 capsid) for Huntington's disease. The company's approach leverages AI/ML-driven capsid and payload engineering to improve targeting precision, reduce dosage requirements, and address scalability limitations that have traditionally confined gene therapy to ultra-rare diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • LTS-101: Gene therapy candidate for CLN2 disease using AAV-Ep+ capsid to deliver TPP1 throughout the CNS.
  • LTS-201
  • AAV.DB-3
  • AAV-Ep+

Products and services

  • LTS-101 Gene therapy candidate exploiting the AAV-Ep+ capsid to deliver functional TPP1 throughout the CNS for treatment of CLN2 disease, a fatal ultra-rare neurodegenerative lysosomal storage disorder.
  • LTS-201 Gene therapy candidate using the AAV-DB-3 capsid targeting the MSH3 gene to inhibit somatic CAG repeat expansion in Huntington's disease, intended to delay or halt disease progression.
  • AAV Capsid Discovery and Engineering Platform Integrated AAV discovery platform combining AI/ML computational methods with unbiased NHP screens to identify novel AAV capsid variants matched to optimized routes of administration; supports potential licensing to other gene therapy developers.

Quantifiable outcome

  • 100x or greater potency vs. traditional AAV5 vectors in non-human primate studies for deep brain regions
  • +4 more outcomes

Companies that use Latus Bio

Customer profile

Segments3 records

Ideal customer profiles3 records

Latus Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Latus Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Dr. Pranam Chatterjee (University of Pennsylvania)minorOthers · 3 November 2025Added to Scientific Advisory Board as an expert in peptide and protein modeling to support Latus Bio's AI/ML-driven capsid and payload engineering strategy.
  • Dr. Philip Kim (University of Toronto)minorOthers · 3 November 2025Added to Scientific Advisory Board as an expert in peptide and protein modeling to advance Latus Bio's three AI/ML focus areas: AAV capsid engineering, payload engineering, and bespoke therapeutic tailoring.
  • Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 2 May 2024Latus Bio was co-founded based on proprietary capsid technology licensed from CHOP. This is the foundational technology relationship underlying the company's entire platform. Beverly Davidson, Ph.D., formerly of CHOP, is the company's founder and SAB Chair.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Latus Bio competitors and assessment

Company assessment

Emerging players

  • StrideBio: Engineered AAV capsid development company with structural and computational design capabilities, directly comparable to Latus's capsid engineering platform focus.
  • Capsida Biotherapeutics: Gene therapy company developing engineered AAV capsids with AI/ML-driven discovery for CNS and other tissues, directly comparable to Latus's capsid engineering platform and AI/ML discovery approach.
  • Affinia Therapeutics: Gene therapy company with engineered AAV capsid platform targeting CNS and other tissues, directly comparable to Latus's approach of capsid engineering for tissue-specific delivery in CNS disorders.

Direct peers

  • Lexeo Therapeutics: Clinical-stage gene therapy company with CNS and cardiac programs leveraging AAV delivery, comparable as a similarly staged competitor in CNS-targeted AAV gene therapy development.
  • Taysha Gene Therapies: Clinical-stage CNS gene therapy company with multiple AAV-based programs for rare neurological diseases, comparable in pipeline focus, stage, and platform approach to Latus.
  • Voyager Therapeutics: Clinical-stage AAV gene therapy company focused on CNS diseases including Huntington's and ALS, with proprietary capsid engineering efforts — overlapping directly with Latus's capsid platform and CNS pipeline strategy.
  • Krystal Biotech: Commercial-stage gene therapy company focused on rare diseases with a non-replicating viral vector platform, providing a comparable business model reference for ultra-rare disease gene therapy commercialization.
  • UniQure: Clinical-stage gene therapy company developing AMT-130 for Huntington's disease using AAV delivery to the CNS — a direct competitor to Latus's LTS-201 program with a similar indication and approach.

Broad incumbents

  • Regenxbio: Established AAV gene therapy platform company with multiple clinical and commercial programs, serving as both a potential licensor/licensing partner and a competitor with deeper manufacturing and clinical capabilities.
  • Spark Therapeutics (Roche): Established gene therapy company (now part of Roche) with commercial gene therapy products, providing a comparable reference for AAV-based therapeutic development and a potential strategic acquirer/licensing partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Latus Bio social profiles

Digital presence

Latus Bio compliance and trust

Trust signal

Compliance4 records

Latus Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Latus Bio leadership team

Management profile

Number of profiles

Profiles12 records

Latus Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Latus Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Latus Bio

What does Latus Bio do?

Latus Bio is a clinical-stage biotechnology company developing AAV-based gene therapy candidates for central nervous system (CNS) disorders. Its lead programs are LTS-201 for Huntington's disease and LTS-101 for CLN2 (Batten) disease, both built on proprietary engineered AAV capsid variants (AAV-DB-3 and AAV-Ep+) discovered through unbiased NHP screening and AI/ML-driven design to enable low-dose, targeted gene delivery to deep brain regions.

Is Latus Bio a public or private company?

Latus Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Latus Bio founded?

Latus Bio was founded in 2024. It employs 11 to 50 people.

Where is Latus Bio based?

Latus Bio is headquartered in Philadelphia, United States, in the North America region.

How does Latus Bio make money?

Two revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are platform Licensing / Strategic Partnerships.

Who are Latus Bio's main competitors?

Emerging players on record are StrideBio, Capsida Biotherapeutics and Affinia Therapeutics. Direct peers are Lexeo Therapeutics, Taysha Gene Therapies, Voyager Therapeutics, Krystal Biotech and UniQure. Broad incumbents are Regenxbio and Spark Therapeutics (Roche).

Does Latus Bio have an API?

No public API is recorded for Latus Bio.

What industry is Latus Bio in?

Latus Bio's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyRepeat offender: Huntington’s and the DNA repair clockLatus Bio published a Nature Communications paper modeling how suppressing MSH3 could slow somatic instability in Huntington's disease, potentially delaying motor onset by at least five years. The model, built on human data, projects a 126% reduction in decline at three years, with preclinical data showing MSH3 knockdown in nonhuman primates. The company plans to file an IND in the third quarter of this year.Business Wire BlogLatus Bio Announces New Preclinical Data Featuring High-Performing Engineered AAV Capsid Variants for Kidney and CNS Diseases at ESGCT 33rd Annual CongressLatus Bio presented new preclinical data at ESGCT 33rd Annual Congress on engineered AAV capsid variants for kidney and CNS diseases. The data show pan-neuronal AAV-PN achieves 40-60% neuronal transduction in NHPs, and kidney-targeting AAV-Kd-1 transduces 80% of glomeruli. The company also highlighted LTS-201 for Huntington's disease and LTS-101 for CLN2 Batten disease.Business Wire BlogLatus Bio Announces Four Abstracts Selected for Presentation at the European Society of Gene and Cell Therapy 33rd Annual CongressLatus Bio announced four abstracts accepted for presentation at the ESGCT 33rd Annual Congress in Hamburg, October 27-30, 2026. The presentations cover proprietary AAV capsids for CNS and kidney targeting, and preclinical data on Huntington's disease and CLN2 Batten disease programs.Business Wire BlogLatus Bio Announces New Data Presentation at American Society of Nephrology (ASN) Kidney Week 2026Latus Bio will present novel engineered AAV capsids with enhanced kidney tropism at ASN Kidney Week 2026. Preclinical data show the lead capsid achieved ~5-fold higher kidney biodistribution than AAV9, transducing 80% of glomeruli in adult non-human primates. The poster presentation highlights broad renal transduction of kidney substructures.TechnicalPhilly startups crossed the $1B venture capital milestone for the third consecutive quarterPhiladelphia startups raised $1.26 billion across 152 deals in Q2 2026, marking the third consecutive quarter the region crossed the $1 billion venture capital milestone, according to the latest PitchBook and National Venture Capital Association Venture Monitor report. However, several top deals went to companies with minimal physical presence in the region, including AI research lab Decart's $300 million raise and cloud platform RunPod's $100 million, both incorporated in Delaware but headquartered in San Francisco. Experts suggest Philadelphia should focus on its strengths in life sciences and healthcare rather than competing in AI, with local biotech Latus Bio's $97 million round highlighting the region's genuine advantages.Business Wire BlogLatus Bio Appoints Bethany Mancilla as Chief Business OfficerLatus Bio appointed Bethany Mancilla as Chief Business Officer, bringing over 25 years of biotech experience. The appointment comes as the company advances LTS-201 for Huntington's disease, with an IND submission expected in the third quarter of 2026.MedCity NewsWindward Bio Secures $165M for Clinical Trials in Asthma, COPD & MoreWindward Bio raised $165 million in a crossover round led by OrbiMed to advance its TSLP-blocking antibody WIN378. The drug is in Phase 2/3 testing with Phase 3 expected to start in Q4, and a COPD trial is planned this quarter. The funding extends its cash runway to reach multiple clinical trial readouts within 12 months.Drug Discovery World (DDW)Drug Discovery World (DDW)The article lists multiple biotechnology and healthcare companies, including Latus Bio, ReAlta Life Sciences, and Parabilis Medicines, that have recently secured significant venture capital financing. These funds are designated to advance various therapeutic pipelines, such as gene therapies, oncology treatments, and antibody engineering, through clinical and regulatory milestones. The reporting aggregates these independent corporate funding events into a single industry update.PharmajournalistLatus Bio Raises $97 Million to Advance Gene TherapiesLatus Bio, Inc. has raised $97 million in Series A financing, including a $43 million extension led by 8VC, with participation from investors including Korea Development Bank and existing backers such as DCVC Bio and BioAdvance. The funding will support two lead gene therapy programs: LTS-201 for Huntington's disease (IND submission planned for Q3 2026) and LTS-101 for CLN2 (already received FDA IND clearance with clinical trial expected to begin Q3 2026). The company's platform combines proprietary engineered AAV capsids with optimized delivery methods to improve targeting, reduce dosage requirements, and enhance safety and scalability across rare and more common CNS conditions.Pharmaceutical TechnologyLatus Bio secures $97m in funding to boost gene therapy accessLatus Bio has closed a $97 million Series A financing round, including a $43 million extension led by 8VC with participation from multiple new and existing investors. The proceeds will fund clinical milestones for two lead candidates: LTS-201 targeting Huntington's disease, with an IND submission planned for Q3 2026, and LTS-101 targeting CLN2 disease, which has received FDA clearance for clinical trials with an investigator-initiated trial starting in Q3 2026.